Advice
in the absence of a submission from the holder of the marketing authorisation:
daratumumab (Darzalex®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice281KB (PDF)
Medicine details
- Medicine name:
- daratumumab (Darzalex)
- SMC ID:
- SMC2895
- Indication:
As monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 19 January 2026